RONALD G CRYSTAL, MD
Osteopathic Medicine at 70 St, New York, NY

2011008, Apr 14, 2011

Jun 4, 2009

12/995851

Ronald G. Crystal - New York NY, US
Philip L. Leopold - Basking Ridge NJ, US
Stefan Worgall - New York NY, US
Julie L. Boyer - New York NY, US

CORNELL UNIVERSITY - Ithaca NY

A61K 39/235, A61K 31/7088, A61P 25/36, A61P 25/30, A61P 25/34, C12N 7/00, C12N 15/63

4241991, 4242331, 514 44 R, 4352351, 4353201

The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector.

2010011, May 13, 2010

Mar 6, 2008

12/529838

Ronald G. Crystal - New York NY, US
Neil R. Hackett - New York NY, US
Adriana Heguy - Forest Hills NY, US
Ben-Gary Harvey - West Hempstead NY, US
Philip L. Leopold - Basking Ridge NJ, US
Ann E. Tilley - New York NY, US
Timothy O'Connor - New York NY, US

Cornell University - Ithaca NY

A61K 38/20, G01N 33/53, A61K 38/45, A61K 38/47, A61K 38/44, A61K 38/21, A61P 11/00

424 852, 435 721, 424 945, 424 9461, 424 944, 424 855

The invention provides a method of determining the likelihood that a smoker will or will not develop chronic obstructive pulmonary disease (COPD) by obtaining a sample from the smoker, analyzing the sample for the expression of a set of biomarkers associated with COPD, and comparing the expression pattern determined in the sample with a standard expression pattern to determine the likelihood that the smoker will or will not develop COPD. The invention further provides a composition, a method of treatment, and methods of determining the efficacy of treatment for COPD.

7863425, Jan 4, 2011

Sep 25, 2008

12/238129

Ronald G Crystal - New York NY, US
Julie L Boyer - New York NY, US

Cornell University - Ithaca NY

C07K 16/00

5303881, 435340

The invention provides a gene transfer vector for inducing an immune response against in a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins of and/or a nucleic acid sequence encoding a monoclonal antibody directed against. The invention further provides a method of producing an immune response against in a mammal comprising administration of the gene transfer vector to the mammal. The invention also provides a monoclonal antibody directed against the Virulence (V) antigen of , as well as a hybridoma cell line producing same and a nucleic acid sequence encoding same.

2003022, Dec 4, 2003

Jun 3, 2002

10/161356

Ronald Crystal - New York NY, US
Masahiro Mae - Tokyo, JP

Cornell Research Foundation, Inc. - Ithaca NY

A61K048/00, A61K038/19, C12N015/861

424/093200, 435/456000, 424/085100

This invention pertains to a method of transferring a gene product to non-pleural tissue in a mammal, wherein a vector comprising an exogenous nucleic acid sequence which encodes a gene product is administered directly to the pleural cavity, the vector transfects pleural tissue cells, the exogenous nucleic acid sequence is expressed to produce the gene product, and the gene product contacts non-pleural tissue, thereby transferring the gene product to the non-pleural tissue.

2004004, Mar 11, 2004

Sep 9, 2003

10/657879

Ronald Crystal - New York NY, US
Todd Rosengart - Highland Park IL, US

Cornell Research Foundation, Inc. - Ithaca NY

A61K048/00, C12N015/861

424/093200, 435/456000

The present invention provides a method of increasing vascularity in a tissue flap. The method comprises contacting a tissue flap with a viral vector, which viral vector comprises a nucleic acid sequence encoding an angiogenic factor, whereby the nucleic acid sequence encoding the angiogenic factor is expressed in the tissue flap and vascularity in the tissue flap is increased.

7687613, Mar 30, 2010

Aug 27, 2003

10/649457

Ronald G. Crystal - New York NY, US
Neil R. Hackett - New York NY, US
Yadi Tan - Zhi-Jiang, CN

Cornell Research Foundation, Inc. - Ithaca NY

C12N 15/11, A61K 48/00

536 231, 514 44

The invention provides a gene transfer vector comprising a humanized nucleic acid sequence encoding an immunogenic portion of one or more exotoxins of and a heterologous sorting signal. The invention also provides a method of producing an immune response against in a host comprising administering to the host the gene transfer vector.

7368553, May 6, 2008

Oct 21, 2004

10/971643

Ronald G. Crystal - New York NY, US
Neil R. Hackett - New York NY, US

Cornell Research Foundation, Inc. - Ithaca NY

C07H 21/04, C12P 21/06, C12N 15/00, C12N 5/00, C12N 15/74

536 235, 435 691, 4352523, 4353201, 435325, 435471

The invention provides an isolated or purified nucleic acid molecule comprising SEQ ID NO:1, which contains cDNA comprising exons 1-5 of a vascular endothelial growth factor (VEGF) joined to genomic DNA comprising introns 5, 6, and 7 and exons 6, 7, and 8 of VEGF and a mutation in one or more of the splice donor, branch point, and splice acceptor regions, which promotes the production of a VEGFisoform. Expression constructs, compositions, and cells comprising such a nucleic acid molecule also are provided by the invention.

2003020, Oct 30, 2003

Apr 23, 2003

10/421351

Ronald Crystal - New York NY, US
Toshiaki Kikuchi - Sendai, JP

Cornell Research Foundation, Inc. - Ithaca NY

A61K048/00, A61K009/127, A61K038/19

424/093200, 424/450000, 424/085100

The present invention provides a method of treating cancer in a mammal comprising administering to the mammal a dendritic cell-mediator, such as CD40L or MDC, and dendritic cells, wherein the dendritic cells can be unmodified or activated, and the dendritic cell-mediator preferably is encoded by a viral vector, such as an adenoviral vector.